Skip to content

Study · Not a test of the peptide alone · 2009

1 result

NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation.

Muhlbradt E, Asatiani E, Ortner E, Wang A, Gelmann EP

Cancer research3 Mar 2009Cited by 16 (Europe PMC)

PMID19258508 (opens in a new tab)PMCIDPMC3740340 (opens in a new tab)DOI10.1158/0008-5472.can-08-3022 (opens in a new tab)PepBankPUB-19258508
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Mechanism

    In PC-3 prostate cancer cells, the NKX3.1 attenuation of IGF-I signaling was not seen when cells were exposed to long-R3-IGF-I.

    In plain wordsIn prostate cancer cells grown in the lab, NKX3.1 did not dampen signaling driven by long-R3-IGF-I.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeNKX3.1 effect on IGF-I signaling with long-R3-IGF-I
    Study

    n: not reported in source

    PC-3 cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    The effect of NKX3.1 on IGF-I signaling was not seen when cells were exposed to long-R3-IGF-I, an IGF-I variant peptide that does not bind to IGFBP-3.
    1 context sentence
    Summary · context
    NKX3.1 expression in PC-3 cells attenuated the ability of insulin-like growth factor-I (IGF-I) to induce phosphorylation of type I IGF receptor (IGF-IR), insulin receptor substrate 1, phosphatidylinositol 3-kinase, and AKT.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.